72.79 0.00 (0.00%)
After hours: 4:32PM EDT
|Bid||69.29 x 2200|
|Ask||74.57 x 800|
|Day's Range||71.15 - 73.59|
|52 Week Range||60.27 - 124.22|
|Beta (3Y Monthly)||2.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||121.61|
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that Jeff Poulton is joining the Company on July 11, 2019 and has been appointed Executive Vice President and Chief Financial Officer (CFO), effective August 13, 2019.
Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.
Kadmon (KDMN) doses first patient in a phase II study of KD025 for the treatment of diffuse cutaneous systemic sclerosis (SSc).
Alnylam (ALNY) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the sale of part of its royalty interest on future global net sales of ONPATTRO™ (patisiran), an RNA interference (RNAi) therapeutic currently being sold by Alnylam Pharmaceuticals, Inc. (ALNY) (Alnylam), to OMERS, the defined benefit pension plan for municipal employees based in the Province of Ontario, Canada. ONPATTRO utilizes Arbutus’s lipid nanoparticle (LNP) technology, which was licensed to Alnylam in November 2012.
Alnylam (ALNY) submits Marketing Authorization Application to the EMA for givosiran in development for the treatment of acute hepatic porphyria.
Regeneron's (REGN) Dupixent gets favorable recommendation from CHMP for moderate-to-severe atopic dermatitis in adolescents aged 12-17 years.
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria (AHP). Givosiran has been granted Priority Medicines (PRIME) Designation by the EMA as well as Orphan Designation in the European Union.
Regeneron (REGN) and partner Sanofi obtain FDA approval for Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis in adults.
Alnylam (ALNY) announces new results from the Global Open-Label Extension study of Onpattro at the 2019 Peripheral Nerve Society (PNS) Annual Meeting.
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today new results from the Global Open-Label Extension (OLE) study of ONPATTRO® (patisiran), an RNAi therapeutic for the treatment of the polyneuropathy of hereditary ATTR (hATTR) amyloidosis. Results were presented at the 2019 Peripheral Nerve Society (PNS) Annual Meeting, being held June 22-26, 2019 in Genoa, Italy.
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today new advances in its RNAi therapeutics platform, including preclinical results demonstrating oral delivery of GalNAc-conjugated small interfering RNAs (siRNAs) – the molecules that mediate RNAi – directed to a liver target. Oral delivery could broaden the clinical and commercial opportunities for RNAi therapeutics, which are currently administered with intravenous or subcutaneous dose administration. The results were presented at the 3rd International Conference on the Long and the Short of Non-Coding RNAs being held June 18-23 in Crete, Greece.
Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]
Alnylam (ALNY) completes enrollment in its ILLUMINATE-A phase III study on lumasiran for the treatment of adults and children with primary hyperoxaluria type 1.
Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNYView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for ALNY with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ALNY are favorable, with net inflows of $4.36 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved ONPATTRO® (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy. ONPATTRO is the first approved RNAi therapeutic in Japan and Alnylam will launch and directly market it in the country.
Regeneron (REGN) reports positive early-stage data on REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma.
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its ILLUMINATE-A Phase 3 study of lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of adults and children with primary hyperoxaluria type 1 (PH1). Alnylam is on track to report topline results from ILLUMINATE-A expected in late 2019 and, if positive, to submit filings for global regulatory approvals starting in early 2020. “We are pleased to have reached two important milestones for our PH1 program, timely completion of enrollment in ILLUMINATE-A – our Phase 3 pivotal study in adults and children – and successful completion of our Phase 1/2 study with positive final results,” said Pritesh J. Gandhi, PharmD, Vice President and General Manager, Lumasiran program at Alnylam.
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Alnylam...
Alnylam Pharmaceuticals, a Massachusetts biopharmaceutical company that specializes in RNA interference therapeutics, is expanding its operations into Philadelphia. “We have a small team there now,” said John Maraganore, the CEO of Cambridge, Mass.-based Alnylam. “There’s a lot of competition for talent up here and there is lot of [life sciences industry] talent in the tri-state area there around Philadelphia.
– Data from Ongoing Open-Label Extension Study Highlight Durable Halting or Reversal of Neuropathy Disease Progression Relative to Baseline and Consistent Safety Profile of ONPATTR